"A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques."
RBD
SARS-CoV-2
antibody
macaque
neutralizing
spike
vaccine
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
21 Dec 2020
21 Dec 2020
Historique:
pubmed:
6
1
2021
medline:
6
1
2021
entrez:
5
1
2021
Statut:
epublish
Résumé
Vaccines that generate robust and long-lived protective immunity against SARS-CoV-2 infection are urgently required. We assessed the potential of vaccine candidates based on the SARS-CoV-2 spike in cynomolgus macaques (
Identifiants
pubmed: 33398285
doi: 10.1101/2020.12.20.422693
pmc: PMC7781324
pii:
doi:
Types de publication
Preprint
Langues
eng
Déclaration de conflit d'intérêts
Competing interests. KL and is an employee and shareholder of Intuitive Biosciences. GB is an employee of Intuitive Biosciences. FS is a founder and employee of Lytic Solutions. DR is an employee of Lytic Solutions. DC and JF are current or former employees of Covance Greenfield Laboratories. KM, MB, and LM are employees of Novartis. The remaining authors declare no conflict of interests.